About: Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis
Creator	Jaiswal, Nishant Kozlakidis, Zisis Sharma, Ajay Pinciroli, Riccardo Das, Rashmi Sankar, Jhuma Dev, Nishanth Jaiswal, Nikita Naik, Ranjan Das, Rashmi Sushree, Samiksha
Source	Medline; PMC
abstract	Background: Anti-malarial drugs inhibit coronaviruses in-vitro. Few published studies have evaluated the safety and efficacy of these drugs in the treatment of COVID-19 infection. Materials and Methods: This is a systematic review and meta-analysis of clinical trials and observational studies. Major database searches were carried out up until June 5, 2020. Participants admitted with RT-PCR-confirmed SARS Cov-2 (COVID-19) infection were included. The “Intervention group” received anti-malarial drugs with or without other drugs (Azithromycin) administered as an adjunct to the standard treatment/care. The “Control group” received treatment except anti-malarial drugs. The primary outcome is “all-cause mortality.” Secondary outcome measures were effects on clinical and laboratory parameters and adverse events. Results: Of 3,472 citations, 17 (six clinical trials and 11 observational studies) studies provided data of 8,071 participants. Compared to the control, Hydroxy-chloroquine (HCQ) has no significant effect on mortality [(OR 0.87; 95% CI 0.46–1.64); eight observational studies; N = 5,944]. Data from a single, small non-randomized trial (N = 42) also reached a similar conclusion (OR 1.94; 95% CI 0.07–50.57; p = 0.69). Compared to the control, HCQ plus Azithromycin (AZM) significantly increased mortality [(OR 2.84; 95% CI 2.19–3.69); four observational studies; N = 2,310]. Compared to the control, risk of any adverse event was significantly increased in HCQ group [(OR 3.35; 95% CI 1.58–7.13); four clinical trials; N = 263]. Compared to control, risk of adverse cardiac events (abnormal ECG, arrhythmia, or QT prolongation) were not significantly increased in HCQ group (but significantly increased in the HCQ plus AZM group). The GRADE evidence generated for all the outcomes was of “very low-quality.” Conclusions: As very low quality evidence suggests an increased risk of mortality and adverse event with HCQ plus Azithromycin combination (not HCQ alone), caution should be exercised while prescribing this combination for treatment of hospitalized adults with COVID-19 infection. Good quality, multi-centric RCTs (including both hospitalized and non-hospitalized patients) are required for any firm recommendation to be made during the ongoing pandemic. OSF Protocol Registration Link: https://osf.io/6zxsu.
has issue date	2020-07-29(xsd:dateTime)
bibo:doi	10.3389/fmed.2020.00482
bibo:pmid	32850924
has license	cc-by
sha1sum (hex)	e5e9886d6afa289fcac4668328be2112f648251f
schema:url	https://doi.org/10.3389/fmed.2020.00482
resource representing a document's title	Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis
has PubMed Central identifier	PMC7403461
has PubMed identifier	32850924
schema:publication	Front Med (Lausanne)
resource representing a document's body	covid:e5e9886d6afa289fcac4668328be2112f648251f#body_text
is schema:about of	named entity 'PUBLISHED' named entity 'STUDIES' named entity 'COVID-19 INFECTION' covid:arg/e5e9886d6afa289fcac4668328be2112f648251f named entity 'in-vitro' named entity 'Anti-malarial Drugs' named entity 'corona virus' named entity 'randomized controlled trials' named entity 'chloroquine' named entity 'antimalarial drugs' named entity 'infection' named entity 'complete blood count' named entity 'HCQ' named entity 'cardiac events' named entity 'symptom' named entity 'clinical trials' named entity 'Control group' named entity 'interleukin-6' named entity '49, 50' named entity 'inflammatory markers' named entity 'HCQ' named entity 'observational studies' named entity 'exposure assessment' named entity 'PCR' named entity 'blood counts' named entity 'COVID-19 infection' named entity 'Data extraction' named entity 'anti-malarial drugs' named entity 'clinical trials' named entity 'coronaviruses' named entity 'Brazil' named entity 'influenza' named entity 'RCT' named entity '95% CI' named entity 'Cochrane' named entity 'highly contagious disease' named entity 'control group' named entity 'observational study' named entity 'HCQ' named entity 'HCQ' named entity 'mortality rate' named entity 'odds ratio' named entity 'Profiler' named entity 'observational studies' named entity 'Chloroquine' named entity 'co-morbidities' named entity 'prospective studies' named entity 'acute phase reactants' named entity '95% confidence interval' named entity 'clinical trials' named entity 'peer-reviewed' named entity 'Google Scholar' named entity 'intracellular space' named entity 'HCQ' named entity 'France' named entity 'case-control studies' named entity 'Denmark' named entity 'hematological' named entity 'leukocyte count' named entity 'meta-analysis' named entity 'cohort studies' named entity 'COVID' named entity 'virus entry' named entity 'Azithromycin' named entity 'Copenhagen' named entity 'outpatient' named entity 'cough' named entity 'symptom' named entity 'self-medicating' named entity 'publication bias' named entity 'categorical data'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software